Radiation and immunotherapy: Renewed allies in the war on cancer.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 23264923)

Published in Oncoimmunology on December 01, 2012

Authors

Steven K Seung1, Brendan Curti, Marka Crittenden, Walter Urba

Author Affiliations

1: Earle A. Chiles Research Institute; Portland, OR USA ; The Oregon Clinic; Portland, OR, USA ; Providence Cancer Center; Portland, OR USA.

Articles by these authors

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15

A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97

Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51

Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol (2002) 1.48

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46

Signaling through OX40 enhances antitumor immunity. Semin Oncol (2010) 1.27

Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther (2002) 1.00

Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol (2005) 0.96

The impact of the myeloid response to radiation therapy. Clin Dev Immunol (2013) 0.92

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer (2008) 0.92

MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J Immunol (2004) 0.91

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med (2012) 0.87

Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood. Clin Cancer Res (2009) 0.80

Targeting and amplification of immune killing of tumor cells by pro-Smac. Int J Cancer (2004) 0.75

Circulating and intratumoral macrophages in patients with hepatocellular carcinoma: correlation with therapeutic approach. Am J Surg (2013) 0.75